NO317873B1 - Farmasoytisk blanding omfattende jernpyrofosfat, anvendelse av jernpyrofosfat for fremstilling av blandingen og fremgangsmate for fremstilling av en dialyselosning. - Google Patents
Farmasoytisk blanding omfattende jernpyrofosfat, anvendelse av jernpyrofosfat for fremstilling av blandingen og fremgangsmate for fremstilling av en dialyselosning. Download PDFInfo
- Publication number
- NO317873B1 NO317873B1 NO19993235A NO993235A NO317873B1 NO 317873 B1 NO317873 B1 NO 317873B1 NO 19993235 A NO19993235 A NO 19993235A NO 993235 A NO993235 A NO 993235A NO 317873 B1 NO317873 B1 NO 317873B1
- Authority
- NO
- Norway
- Prior art keywords
- iron
- dialysis
- patients
- dialysate
- pyrophosphate
- Prior art date
Links
- CADNYOZXMIKYPR-UHFFFAOYSA-B ferric pyrophosphate Chemical compound [Fe+3].[Fe+3].[Fe+3].[Fe+3].[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O CADNYOZXMIKYPR-UHFFFAOYSA-B 0.000 title claims abstract description 69
- 239000000385 dialysis solution Substances 0.000 title claims abstract description 43
- 238000000034 method Methods 0.000 title claims abstract description 33
- 239000000203 mixture Substances 0.000 title claims description 20
- 238000002360 preparation method Methods 0.000 title claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 title abstract description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 500
- 229910052742 iron Inorganic materials 0.000 claims abstract description 236
- 238000000502 dialysis Methods 0.000 claims abstract description 121
- 238000001631 haemodialysis Methods 0.000 claims abstract description 55
- 230000000322 hemodialysis Effects 0.000 claims abstract description 54
- 239000012141 concentrate Substances 0.000 claims description 33
- 239000000243 solution Substances 0.000 claims description 30
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 4
- 238000007911 parenteral administration Methods 0.000 claims description 4
- 238000001802 infusion Methods 0.000 abstract description 9
- 150000001875 compounds Chemical class 0.000 abstract description 7
- 235000007144 ferric diphosphate Nutrition 0.000 abstract description 7
- 239000011706 ferric diphosphate Substances 0.000 abstract description 7
- 229940036404 ferric pyrophosphate Drugs 0.000 abstract description 7
- 230000008569 process Effects 0.000 abstract description 5
- 238000001990 intravenous administration Methods 0.000 description 59
- 210000002966 serum Anatomy 0.000 description 50
- 102000004338 Transferrin Human genes 0.000 description 47
- 108090000901 Transferrin Proteins 0.000 description 47
- 239000012581 transferrin Substances 0.000 description 47
- 108090000394 Erythropoietin Proteins 0.000 description 32
- 102000003951 Erythropoietin Human genes 0.000 description 31
- 210000004369 blood Anatomy 0.000 description 31
- 239000008280 blood Substances 0.000 description 31
- 229940105423 erythropoietin Drugs 0.000 description 31
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 31
- 238000002560 therapeutic procedure Methods 0.000 description 29
- 238000011282 treatment Methods 0.000 description 29
- 102000001554 Hemoglobins Human genes 0.000 description 27
- 108010054147 Hemoglobins Proteins 0.000 description 27
- 206010022971 Iron Deficiencies Diseases 0.000 description 25
- 210000002381 plasma Anatomy 0.000 description 25
- 102000008857 Ferritin Human genes 0.000 description 24
- 108050000784 Ferritin Proteins 0.000 description 24
- 238000008416 Ferritin Methods 0.000 description 24
- 238000012423 maintenance Methods 0.000 description 20
- 241000283973 Oryctolagus cuniculus Species 0.000 description 18
- 239000012528 membrane Substances 0.000 description 17
- 150000002506 iron compounds Chemical class 0.000 description 16
- 238000012546 transfer Methods 0.000 description 15
- 210000004379 membrane Anatomy 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 12
- 230000008859 change Effects 0.000 description 10
- 238000012384 transportation and delivery Methods 0.000 description 10
- 208000020832 chronic kidney disease Diseases 0.000 description 9
- 230000002950 deficient Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 238000005534 hematocrit Methods 0.000 description 9
- 210000004303 peritoneum Anatomy 0.000 description 9
- 102000008133 Iron-Binding Proteins Human genes 0.000 description 8
- 108010035210 Iron-Binding Proteins Proteins 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 231100000331 toxic Toxicity 0.000 description 7
- 230000002588 toxic effect Effects 0.000 description 7
- 235000005911 diet Nutrition 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 238000009792 diffusion process Methods 0.000 description 6
- 201000000523 end stage renal failure Diseases 0.000 description 6
- 230000002489 hematologic effect Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 208000028208 end stage renal disease Diseases 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 210000001995 reticulocyte Anatomy 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000000108 ultra-filtration Methods 0.000 description 5
- 230000003442 weekly effect Effects 0.000 description 5
- 208000037157 Azotemia Diseases 0.000 description 4
- 206010065973 Iron Overload Diseases 0.000 description 4
- 210000000683 abdominal cavity Anatomy 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 208000007502 anemia Diseases 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 4
- 235000011180 diphosphates Nutrition 0.000 description 4
- 239000000004 hemodialysis solution Substances 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 208000009852 uremia Diseases 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 208000013038 Hypocalcemia Diseases 0.000 description 3
- 208000001953 Hypotension Diseases 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 208000003455 anaphylaxis Diseases 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 3
- 238000011067 equilibration Methods 0.000 description 3
- 150000003278 haem Chemical class 0.000 description 3
- 238000002615 hemofiltration Methods 0.000 description 3
- 230000000705 hypocalcaemia Effects 0.000 description 3
- 230000036543 hypotension Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 235000020796 iron status Nutrition 0.000 description 3
- MVZXTUSAYBWAAM-UHFFFAOYSA-N iron;sulfuric acid Chemical compound [Fe].OS(O)(=O)=O MVZXTUSAYBWAAM-UHFFFAOYSA-N 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 230000009469 supplementation Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 210000000504 visceral peritoneum Anatomy 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920000388 Polyphosphate Polymers 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 210000003815 abdominal wall Anatomy 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000003433 contraceptive agent Substances 0.000 description 2
- 230000002254 contraceptive effect Effects 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002706 hydrostatic effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229940090441 infed Drugs 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 210000000505 parietal peritoneum Anatomy 0.000 description 2
- 210000003200 peritoneal cavity Anatomy 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 229920002492 poly(sulfone) Polymers 0.000 description 2
- 239000001205 polyphosphate Substances 0.000 description 2
- 235000011176 polyphosphates Nutrition 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 230000003307 reticuloendothelial effect Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000037317 transdermal delivery Effects 0.000 description 2
- 230000009278 visceral effect Effects 0.000 description 2
- RLSFDUAUKXKPCZ-UITAMQMPSA-N (z)-3-amino-1-[3-(trifluoromethyl)-6,8-dihydro-5h-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)but-2-en-1-one Chemical compound C1CN(C(=NN=2)C(F)(F)F)C=2CN1C(=O)\C=C(/N)CC1=CC(F)=C(F)C=C1F RLSFDUAUKXKPCZ-UITAMQMPSA-N 0.000 description 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- GEZAUFNYMZVOFV-UHFFFAOYSA-J 2-[(2-oxo-1,3,2$l^{5},4$l^{2}-dioxaphosphastannetan-2-yl)oxy]-1,3,2$l^{5},4$l^{2}-dioxaphosphastannetane 2-oxide Chemical compound [Sn+2].[Sn+2].[O-]P([O-])(=O)OP([O-])([O-])=O GEZAUFNYMZVOFV-UHFFFAOYSA-J 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 208000003241 Fat Embolism Diseases 0.000 description 1
- CZNVSLGYWMSMKE-OPDGVEILSA-K Ferric gluconate Chemical compound [Fe+3].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O CZNVSLGYWMSMKE-OPDGVEILSA-K 0.000 description 1
- 206010016803 Fluid overload Diseases 0.000 description 1
- 101000766307 Gallus gallus Ovotransferrin Proteins 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 1
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 206010027417 Metabolic acidosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010034650 Peritoneal adhesions Diseases 0.000 description 1
- 206010034665 Peritoneal fibrosis Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- NOSIYYJFMPDDSA-UHFFFAOYSA-N acepromazine Chemical compound C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 NOSIYYJFMPDDSA-UHFFFAOYSA-N 0.000 description 1
- 229960005054 acepromazine Drugs 0.000 description 1
- JOJMQRPFXIKGJG-UHFFFAOYSA-N acetic acid;carbonic acid Chemical compound CC(O)=O.OC(O)=O JOJMQRPFXIKGJG-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 229940008201 allegra Drugs 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000022400 anemia due to chronic disease Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000000823 artificial membrane Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229940064804 betadine Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 1
- 229960001113 butorphanol Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 238000007816 calorimetric assay Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 231100000060 cardiovascular toxicity Toxicity 0.000 description 1
- 230000007681 cardiovascular toxicity Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007485 conventional hemodialysis Methods 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000007728 cost analysis Methods 0.000 description 1
- -1 cupraphan Polymers 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000010437 erythropoiesis Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000004079 fireproofing Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 102000044890 human EPO Human genes 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 201000005991 hyperphosphatemia Diseases 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000002642 intravenous therapy Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- DCYOBGZUOMKFPA-UHFFFAOYSA-N iron(2+);iron(3+);octadecacyanide Chemical compound [Fe+2].[Fe+2].[Fe+2].[Fe+3].[Fe+3].[Fe+3].[Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] DCYOBGZUOMKFPA-UHFFFAOYSA-N 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 210000002311 liver mitochondria Anatomy 0.000 description 1
- 238000011418 maintenance treatment Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 150000004690 nonahydrates Chemical group 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000003330 peritoneal dialysis fluid Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 229960003351 prussian blue Drugs 0.000 description 1
- 239000013225 prussian blue Substances 0.000 description 1
- 238000011555 rabbit model Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 231100000828 respiratory toxicity Toxicity 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000002151 serous membrane Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229910001432 tin ion Inorganic materials 0.000 description 1
- 230000003868 tissue accumulation Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 231100000925 very toxic Toxicity 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1654—Dialysates therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
- A61M1/287—Dialysates therefor
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- External Artificial Organs (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/775,595 US6689275B1 (en) | 1996-12-31 | 1996-12-31 | Method and pharmaceutical composition for replacing iron losses in dialysis patients |
| US5531597P | 1997-08-07 | 1997-08-07 | |
| PCT/US1997/023719 WO1998029434A1 (en) | 1996-12-31 | 1997-12-30 | Method and pharmaceutical composition for iron delivery in hemodialysis and peritoneal dialysis patients |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO993235D0 NO993235D0 (no) | 1999-06-29 |
| NO993235L NO993235L (no) | 1999-08-27 |
| NO317873B1 true NO317873B1 (no) | 2004-12-27 |
Family
ID=26734087
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19993235A NO317873B1 (no) | 1996-12-31 | 1999-06-29 | Farmasoytisk blanding omfattende jernpyrofosfat, anvendelse av jernpyrofosfat for fremstilling av blandingen og fremgangsmate for fremstilling av en dialyselosning. |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP0951470B1 (ja) |
| JP (2) | JP3955639B2 (ja) |
| AT (1) | ATE311180T1 (ja) |
| AU (1) | AU736053B2 (ja) |
| BR (1) | BR9713653B1 (ja) |
| CA (1) | CA2276442C (ja) |
| DE (1) | DE69734781T2 (ja) |
| DK (1) | DK0951470T3 (ja) |
| EA (1) | EA002479B1 (ja) |
| ES (1) | ES2255115T3 (ja) |
| HK (1) | HK1023350A1 (ja) |
| NO (1) | NO317873B1 (ja) |
| NZ (1) | NZ336319A (ja) |
| PL (1) | PL191377B1 (ja) |
| SI (1) | SI20151A (ja) |
| TR (1) | TR199901518T2 (ja) |
| WO (1) | WO1998029434A1 (ja) |
| YU (1) | YU31299A (ja) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5906978A (en) * | 1996-08-14 | 1999-05-25 | Hemocleanse, Inc. | Method for iron delivery to a patient by transfer from dialysate |
| US7670491B2 (en) * | 1998-10-20 | 2010-03-02 | Advanced Renal Technologies | Buffered compositions for dialysis |
| AU7607800A (en) | 1999-09-22 | 2001-04-24 | Advanced Renal Technologies | High citrate dialysate and uses thereof |
| DE19951471A1 (de) * | 1999-10-26 | 2001-05-03 | Forssmann Wolf Georg | Verwendung von Urodilatin zur Behandlung chronischer Niereninsuffizienz mit Nierenrestfunktionen |
| CA2544235C (en) * | 2003-10-28 | 2013-12-10 | Emory University | Dialysates and methods and systems related thereto |
| US8187467B2 (en) * | 2003-12-30 | 2012-05-29 | Ajay Gupta | Parenteral administration of pyrophosphate for prevention or treatment of phosphate or pyrophosphate depletion |
| SE0400523D0 (sv) | 2004-03-01 | 2004-03-01 | Gambro Lundia Ab | A medical solution, a method for producing said medical solution and use thereof |
| SE0402507D0 (sv) | 2004-10-14 | 2004-10-14 | Gambro Lundia Ab | Medicinsk lösning, förfarande för framställning och användning därav |
| US7586589B2 (en) * | 2005-09-24 | 2009-09-08 | Beckman Coulter, Inc. | Methods of determination of responsiveness to erythropoietin treatment |
| US7816404B2 (en) * | 2007-07-20 | 2010-10-19 | Rockwell Medical Technologies, Inc. | Methods for the preparation and use of ferric pyrophosphate citrate chelate compositions |
| US7658952B2 (en) * | 2007-10-11 | 2010-02-09 | Baxter International Inc. | Dialysis solutions containing pyrophosphates |
| EP2560663B1 (en) * | 2010-04-23 | 2016-06-22 | Baxter International Inc. | Methods and compositions for reducing or preventing vascular calcification during peritoneal dialysis therapy |
| AU2015200995B2 (en) * | 2010-04-23 | 2016-09-08 | Baxter Healthcare S.A. | Methods and compositions for reducing or preventing vascular calcification during peritoneal dialysis therapy |
| CA2900043A1 (en) * | 2013-02-01 | 2014-08-07 | Charak Llc | Methods of treating iron deficiency with soluble ferric pyrophosphate |
| EP3065762B1 (en) * | 2013-11-05 | 2018-10-10 | Rockwell Medical Inc. | Methods of reducing doses of erythropoietin stimulating agents in hyporesponsive patients |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3530216A (en) * | 1967-10-05 | 1970-09-22 | Hoffmann La Roche | Vitamin compositions comprising riboflavin-5-phosphate and ferric pyrophosphate soluble |
| US3911915A (en) * | 1972-09-05 | 1975-10-14 | Einstein Coll Med | Dialytic introduction of maltose into bloodstream |
| JPS5125238B2 (ja) * | 1973-08-14 | 1976-07-29 | ||
| US4756838A (en) * | 1980-02-21 | 1988-07-12 | Veltman Preston Leonard | Preparation of dry dialysate products |
| JPH0696586B2 (ja) * | 1987-03-17 | 1994-11-30 | 花王株式会社 | ヘキソ−スリン酸第一鉄塩及びその製造法並びにこれを含有する鉄供給剤 |
| JPH0525051A (ja) * | 1991-07-19 | 1993-02-02 | Meiji Seika Kaisha Ltd | 貧血予防・治療剤 |
| JP3167402B2 (ja) * | 1992-02-25 | 2001-05-21 | 仙味エキス株式会社 | 鉄吸収促進組成物 |
-
1997
- 1997-12-30 WO PCT/US1997/023719 patent/WO1998029434A1/en active IP Right Grant
- 1997-12-30 BR BRPI9713653-0A patent/BR9713653B1/pt not_active IP Right Cessation
- 1997-12-30 JP JP53014898A patent/JP3955639B2/ja not_active Expired - Lifetime
- 1997-12-30 TR TR1999/01518T patent/TR199901518T2/xx unknown
- 1997-12-30 AU AU56172/98A patent/AU736053B2/en not_active Expired
- 1997-12-30 DK DK97952598T patent/DK0951470T3/da active
- 1997-12-30 CA CA2276442A patent/CA2276442C/en not_active Expired - Lifetime
- 1997-12-30 AT AT97952598T patent/ATE311180T1/de active
- 1997-12-30 NZ NZ336319A patent/NZ336319A/xx not_active IP Right Cessation
- 1997-12-30 SI SI9720087A patent/SI20151A/sl unknown
- 1997-12-30 DE DE69734781T patent/DE69734781T2/de not_active Expired - Lifetime
- 1997-12-30 YU YU31299A patent/YU31299A/sh unknown
- 1997-12-30 EP EP97952598A patent/EP0951470B1/en not_active Expired - Lifetime
- 1997-12-30 ES ES97952598T patent/ES2255115T3/es not_active Expired - Lifetime
- 1997-12-30 EA EA199900609A patent/EA002479B1/ru not_active IP Right Cessation
- 1997-12-30 PL PL334437A patent/PL191377B1/pl unknown
-
1999
- 1999-06-29 NO NO19993235A patent/NO317873B1/no not_active IP Right Cessation
-
2000
- 2000-04-26 HK HK00102462A patent/HK1023350A1/xx not_active IP Right Cessation
-
2007
- 2007-01-12 JP JP2007004535A patent/JP4753379B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| YU31299A (sh) | 2002-08-12 |
| WO1998029434A1 (en) | 1998-07-09 |
| AU736053B2 (en) | 2001-07-26 |
| AU5617298A (en) | 1998-07-31 |
| DE69734781T2 (de) | 2006-07-20 |
| PL191377B1 (pl) | 2006-05-31 |
| TR199901518T2 (xx) | 1999-12-21 |
| ES2255115T3 (es) | 2006-06-16 |
| JP4753379B2 (ja) | 2011-08-24 |
| EA002479B1 (ru) | 2002-06-27 |
| EP0951470A1 (en) | 1999-10-27 |
| JP2007106775A (ja) | 2007-04-26 |
| CA2276442C (en) | 2012-01-17 |
| SI20151A (sl) | 2000-08-31 |
| BR9713653B1 (pt) | 2013-05-21 |
| HK1023350A1 (en) | 2000-09-08 |
| EP0951470B1 (en) | 2005-11-30 |
| DK0951470T3 (da) | 2006-03-27 |
| JP2002531051A (ja) | 2002-09-17 |
| PL334437A1 (en) | 2000-02-28 |
| CA2276442A1 (en) | 1998-07-09 |
| EP0951470A4 (en) | 2003-05-02 |
| JP3955639B2 (ja) | 2007-08-08 |
| EA199900609A1 (ru) | 1999-12-29 |
| DE69734781D1 (de) | 2006-01-05 |
| NZ336319A (en) | 2000-12-22 |
| BR9713653A (pt) | 2000-04-11 |
| NO993235D0 (no) | 1999-06-29 |
| NO993235L (no) | 1999-08-27 |
| ATE311180T1 (de) | 2005-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6779468B1 (en) | Method and pharmaceutical composition for iron delivery in hemodialysis and peritoneal dialysis patients | |
| JP4753379B2 (ja) | 血液透析及び腹膜透析患者における鉄デリバリーのための方法及び医薬組成物 | |
| US6689275B1 (en) | Method and pharmaceutical composition for replacing iron losses in dialysis patients | |
| US4889634A (en) | Dialysate solution containing hydroxypropyl-beta-cyclodextrin and method of using same | |
| JP5690040B2 (ja) | 重炭酸塩ベースの腹膜透析溶液 | |
| AU2003299683B2 (en) | Biocompatible dialysis fluids containing icodextrins | |
| Macdougall | Evolution of iv iron compounds over the last century | |
| Sam et al. | Composition and clinical use of hemodialysates | |
| US5945449A (en) | Sterile bicarbonate concentrate | |
| CN105380936A (zh) | 铁代谢改善剂 | |
| EP0153164B1 (en) | Peritoneal dialysis and compositions for use therein | |
| EP0078832A1 (en) | DIALYSIS SOLUTION CONTAINING GLYCEROL. | |
| WO2001000204A1 (en) | Method and pharmaceutical composition for parenteral administration of iron | |
| Eliahou et al. | Acetate and bicarbonate in the correction of uraemic acidosis | |
| Parsons et al. | Use of dialysis in the treatment of renal failure in liver disease | |
| MXPA99006187A (en) | Method and pharmaceutical composition for iron delivery in hemodialysis and peritoneal dialysis patients | |
| Feriani et al. | Continuous ambulatory peritoneal dialysis with bicarbonate buffer-a pilot study | |
| Van Biesen et al. | Further animal and human experience with a 0.6% amino acid/1.4% glycerol peritoneal dialysis solution | |
| EP3452136A1 (en) | Dialysis concentrate | |
| Böhler | Treatment of acute renal failure in intensive care patients | |
| Woerlee et al. | Properties of Intravenous Fluids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |